FB-TW

Showing posts with label CAC. Show all posts
Showing posts with label CAC. Show all posts

Tuesday, February 10, 2015

Coronary Calcium Imaging Improves on Framingham Score Regardless of Symptoms in Analysis - Medscape

Coronary Calcium Imaging Improves on Framingham Score Regardless of Symptoms in Analysis

HOUSTON, TX — In asymptomatic and symptomatic patients at low risk for coronary artery disease, the use of coronary artery calcium (CAC) imaging improves long-term prediction of risk beyond that established by the Framingham Risk Score (FRS) and exercise-treadmill and stress-perfusion testing, according to the results of a new study[1]. The same findings were observed even among individuals who met the appropriate-use criteria for functional testing, report investigators.
"What we were able to show was that across all Framingham Risk Scores, calcium scoring significantly added in terms of predicting outcome and reclassifying risk in these individuals," senior investigator Dr John Mahmarian (Houston Methodist DeBakey Heart and Vascular Center, TX) told heartwire . "There have been several studies looking at low Framingham Risk Score patients, and this study bolsters the argument that calcium scoring adds tremendously in that [low-risk] group."
Furthermore, the researchers also looked at several treadmill variables—peak-exercise capacity, exercise-tolerance test (ETT) ischemia, and the Duke treadmill score—and found the addition of the calcium score to any of the variables significantly improved the reclassification of risk beyond that achieved with the clinical-data and functional-test results.
The results of the study, which was led by Dr Su Min Chang (Houston Methodist DeBakey Heart and Vascular Center), are published February 9, 2015 in JACC: Cardiovascular Imaging.

===============================================================
Read the complete article here.

Tuesday, March 12, 2013

Statins drugs cause heart disease.

New research shows that statins, drugs which lower cholesterol, cause heart disease.
 
New research shows that statins, drugs which lower cholesterol, cause heart disease. These drugs cause calcified plaques to form in coronary arteries in humans, thus causing or worsening heart disease.
A new study shows that the use of statins increases calcified plaque in coronary arteries. Coronary artery calcification (CAC) is a measure of coronary atherosclerosis, predicts coronary heart disease (CAD), and has been described as the strongest predictor of cardiac risk in patients with no symptoms. The study was led by Ryo Nakazato of the Cedars-Sinai Heart Institute and Department of Imaging, Cedars-Sinai Medical Center, Los Angeles and examined 6673 subjects with no known coronary heart disease. One group of 2413 was on statins and another group of 4260 wasn't on statins. Those who used statins had a higher prevalence of obstructive coronary artery disease and a higher number of coronary segments that had calcified plaques. The study was published in the journal Atherosclerosis.
Another recent study on diabetic subjects with advanced atherosclerosis also shows that frequent statin use causes accelerated coronary artery calcification. The study, published in the journal Diabetes Care,also shows that in those who weren’t initially using statins, the progression of coronary and abdominal artery calcification was significantly increased in those who used statins frequently.
Furthermore, another new study published in the Journal of the American College of Cardiology Foundation Cardiovascular Imaging also shows that CAC is associated with heart failure.
Thus statin drugs can cause coronary heart disease by increasing coronary artery calcification in healthy and diabetic subjects. Previous research has also shown that statins don’t reduce the risk of all-cause mortality. Because coronary artery calcification strongly predicts coronary heart disease, and statins increase artery calcification, their wide-spread use must be questioned.
If you use statins, discuss their use with your doctor, and preferably with a cardiologist.
CAC can be determined with electron beam computed tomography or multidetector computed tomography scan. Ask your cardiologist to undergo CAC scoring so you can evaluate the effects of the statins on your arteries and to make an educated decision if you should discontinue them or not.
Read more: http://digitaljournal.com/article/334943#ixzz2NHsPS6Y6

Sunday, October 14, 2012

Results of my second serial CAC Scan just in.

I have been working hard on slowing plaque growth for several years but mostly in the last year and a half because I had my first viable CAC scan to provide a measuring point baseline for reference.

Other comments on the report follow.
  • IMPRESSION: Stable exam compared to Sept 15, 2011

  • PATIENT: 69 year old man with no cardiac symptoms but a past history of cardiovascular disease resulting in 6 MI events over a 17 year period. His current stress level is low. He has a history of prior cardiac procedures including CABG (1x), Angiography and Coronary Stent (3x). He has a family history of stroke and heart disease in a first or second degree relative.

  • YOUR AGATSTON CALCIUM SCORE IS: 1072.3

  • Your current EBT heart was compared to your most recent prior scan and the progression of calcified plaque is less than 15% annually. This is a very good result and is consistent with a low risk for coronary event over the next few years.

Encouraging but no resting on my laurels. The 22% annualized plaque growth in the RCA is a matter of concern reminding me that further improvement is necessary so adjustments may have to be made in my diet etc.


Prior Scan was Sept 15, 2011
Current Scan Oct 5, 2012
My assessment is that it looks pretty good except for % change on LMCA and the RCA
That line below the chart that ends with 4% is good.
Have consult with doctor tomorrow (10/15/2012). Stay tuned for a more qualified analysis.




Note my treatment plan which seems to be paying off is that of the Track Your Plaque Program. It primarily consists of diet and supplements with minimal drug intervention (especially 'no statins' which I do not tolerate). It includes advanced lipid analysis then treating atherogenic ones such as Lp(a) and apo B or LDL particle number and particle size.

Friday, September 28, 2012

Vascular Calcification Is Increased With Statin Use


Progression of Vascular Calcification Is Increased With Statin Use in the Veterans Affairs Diabetes Trial (VADT)

  1. for the VADT Investigators
+ Author Affiliations
  1. 1Phoenix VA Health Care System, Phoenix, Arizona
  2. 2Cooperative Studies Program Coordinating Center, Hines, Illinois
  1. Corresponding author: Aramesh Saremi, Aramesh.Saremi@va.gov.

Abstract

OBJECTIVE To determine the effect of statin use on progression of vascular calcification in type 2 diabetes (T2DM).
                   
RESEARCH DESIGN AND METHODS Progression of coronary artery calcification (CAC) and abdominal aortic artery calcification (AAC) was assessed according to the frequency of statin use in 197 participants with T2DM.
                   
RESULTS After adjustment for baseline CAC and other confounders, progression of CAC was significantly higher in more frequent statin users than in less frequent users (mean ± SE, 8.2 ± 0.5 mm3 vs. 4.2 ± 1.1 mm3; P < 0.01). AAC progression was in general not significantly increased with more frequent statin use; in a subgroup of participants initially not receiving statins, however, progression of both CAC and AAC was significantly increased in frequent statin users.
                   
CONCLUSION More frequent statin use is associated with accelerated coronary artery calcification in T2DM patients with advanced atherosclerosis.
===========================================================================================================
Read the complete article here.

Friday, September 7, 2012

Vascular Calcification Is Increased With Statin - ADA

Progression of Vascular Calcification Is Increased With Statin Use in the Veterans Affairs Diabetes Trial (VADT)

 
 Author Affiliations
  1. 1Phoenix VA Health Care System, Phoenix, Arizona
  2. 2Cooperative Studies Program Coordinating Center, Hines, Illinois
Corresponding author: Aramesh Saremi, Aramesh.Saremi@va.gov.

Abstract

OBJECTIVE To determine the effect of statin use on progression of vascular calcification in type 2 diabetes (T2DM).
                   
RESEARCH DESIGN AND METHODS Progression of coronary artery calcification (CAC) and abdominal aortic artery calcification (AAC) was assessed according to the frequency of statin use in 197 participants with T2DM.
                   
RESULTS After adjustment for baseline CAC and other confounders, progression of CAC was significantly higher in more frequent statin users than in less frequent users (mean ± SE, 8.2 ± 0.5 mm3 vs. 4.2 ± 1.1 mm3; P < 0.01). AAC progression was in general not significantly increased with more frequent statin use; in a subgroup of participants initially not receiving statins, however, progression of both CAC and AAC was significantly increased in frequent statin users.
                   
CONCLUSION More frequent statin use is associated with accelerated coronary artery calcification in T2DM patients with advanced atherosclerosis.
 
© 2012 by the American Diabetes Association.
=========================================================
Read the full article here.

Wednesday, August 22, 2012

Coronary artery calcium bests other risk markers.. - O'Riordan

Coronary artery calcium bests other risk markers for CVD risk assessment

August 22, 2012 Michael O'Riordan


Winston-Salem, NC - A comparison of multiple risk markers suggests that coronary artery calcium (CAC) provides the most improvement in the assessment of cardiovascular disease risk in patients at intermediate risk for future events [1]. Ankle-brachial index, high-sensitivity C-reactive protein (CRP), family history, and CAC were all independent risk predictors for incident coronary heart disease and cardiovascular disease, but CAC provided superior discrimination and risk reclassification compared with the other risk markers.
 
"If you go to any cardiologist, all that they're doing while you're sitting in front of them is trying to put you into one of three risk categories," lead investigator Dr Joseph Yeboah (Wake Forest University School of Medicine, Winston-Salem, NC) told heartwire. "We know what we should do for low-risk people. We just emphasize lifestyle changes, and most of the time over 10 years nothing happens to them. We know that in high-risk patients, in addition to lifestyle, certain medications work. What we don't know how to do is treat people who fall into the intermediate group. They're in no-man's land. Yet we know a chunk of the people who have heart attacks are within this group. This tells us that there are people who are wrongly put into this category based on current risk tools."
 
In an editorial accompanying the study [2], Dr J Michael Gaziano (Brigham and Women's Hospital, Boston, MA) and Dr Peter Wilson (Atlanta Veteran Affairs Medical Center, GA) agree that a CAC scan might help guide clinical decisions, but radiation exposure and costs remain important considerations. "Coronary artery calcium findings also are somewhat resistant to change even in the face of improvement in risk factors and may be useful as a single measure for assessment, especially when refinement of a risk estimate is important, but might not be useful for tracking risk over time," according to the editorialists.
 
The study and editorial are published in the August 22, 2012 issue of the Journal of the American Medical Association.

Data from the MESA study
Using data from the Multiethnic Study of Atherosclerosis (MESA), the researchers identified 1330 intermediate-risk patients without diabetes mellitus who had data available for all six of the following cardiovascular risk markers: CAC, carotid intima-media thickness (CIMT), ankle-brachial index (ABI), brachial flow-mediated dilation (FMD), and CRP, as well as family history of coronary heart disease. The purpose of the study, explained Yeboah, was to test the effectiveness of these "top-tier" risk markers for cardiovascular risk stratification when added to conventional risk scores in the same group of patients.
 
After a median follow-up of 7.6 years, there were 123 cardiovascular events. CAC, ABI, high-sensitivity CRP, and family history of coronary heart disease were independently associated with incident coronary heart disease, defined as a composite of MI, angina followed by revascularization, resuscitated cardiac arrest, and coronary heart disease death.
Association of risk markers with incident coronary heart disease*

Risk markerHazard ratio (95% CI)
Ankle-brachial index0.79 (0.66-0.96)
Brachial flow-mediated dilation0.93 (0.74-1.16)
Coronary artery calcium 2.60 (1.94-3.50)
Carotid intima-media thickness1.17 (0.96-1.45)
Family history2.18 (1.38-3.42)
High-sensitivity CRP1.28 (1.00-1.64)

*Adjusted for age, sex, race/ethnicity, systolic blood pressure, total cholesterol, HDL cholesterol, smoking status, body-mass index, use of blood-pressure medication, and use of statins

For coronary and cardiovascular disease events, which included stroke and cardiovascular death, the addition of each of the six markers to the Framingham risk score significantly improved the discrimination of clinical events compared with the Framingham score alone. The area under the curve (AUC) improved for all the risk markers but improved the most with CAC scoring. With the addition of CAC, the AUC improved from 0.623 to 0.784.
 
Similarly, CAC fared best when assessed by net reclassification improvement (NRI), a measure of the relative improvement in the classification of risk with the additional variable. The researchers note that 25.5% of the events were reclassified correctly to the high-risk category, while 40.4% of nonevents were reclassified into the low-risk group. The NRI for the addition of CAC to the Framingham risk score, plus race/ethnicity, was 0.659, the highest reported NRI of the six risk markers.

CAC fares best, but there are caveats
While CAC performed the best of the six markers, Yeboah said that there are important caveats to the results. Echoing the editorialists, he told heartwire that only CAC scoring exposes patients to a small, but not trivial, amount of radiation. He said the long-term effects of radiation on patients remain unknown and will need to be determined before widespread screening using CAC can be used to help the decision-making process.
 
There would be no benefit to society if we drastically reduce the number of heart attacks only to find out that everybody is developing cancer.
 
"There would be no benefit to society if we drastically reduce the number of heart attacks only to find out that everybody is developing cancer," said Yeboah.
 
In addition, there are no outcome studies showing that adding CAC screening to traditional risk scoring systems in intermediate-risk patients reduces the risk of cardiovascular events. If these caveats are addressed, said Yeboah, then CAC screening should be used for the 28 million US adults who fall within the intermediate-risk category. Currently, the American Heart Association and the European Society of Cardiology say it is "reasonable" to use CAC as a screening method for intermediate-risk patients.
 
In their editorial, Gaziano and Wilson note that research into general cardiovascular disease prevention is timely, given that the National Cholesterol Education Program (NCEP) Adult Treatment Panel 4 treatment guidelines are expected this year, and the addition of novel risk markers to Framingham or the Reynolds risk score might help physicians make a decision about whether or not to start a patient on lifelong statin therapy.
 
They note, however, that if a patient is near a boundary for lipid-lowering therapy, the doctor can simply choose to see the patient again in a few months rather than order a costly CAC imaging test. Reassessing vascular risk with a patient visit to repeat tests might improve accuracy and reveal trends that could help guide treatment decisions, according to Gaziano and Wilson. While CAC scores can help augment the risk-assessment process, they have limited utility in tracking a patient's progress, as the test is not likely to be repeated over time.
============================================================
Read the full article here.

Tuesday, August 21, 2012

Heart Calcium Scan Most Effective in Predicting Risk of Heart Disease

Released:8/20/2012 10:45 AM EDT
Source:Wake Forest Baptist Medical Center

Newswise — WINSTON-SALEM, N.C. – Aug. 21, 2012 – Heart calcium scans are far superior to other assessment tools in predicting the development of cardiovascular disease in individuals currently classified at intermediate risk by their doctors, according to researchers at Wake Forest Baptist Medical Center.

The test, known as coronary artery calcium (CAC), uses a CT scan to detect calcium build-up in the arteries around the heart. The study findings are presented in the Aug. 22 issue of the Journal of the American Medical Association.

Current medical guidelines recommend classifying individuals as high, intermediate or low risk using the Framingham Risk Score (FRS), a cardiovascular risk-prediction model. However, doctors realize that the model isn’t perfect and that the intermediate group actually includes some individuals who could benefit from more aggressive drug therapy, as well as individuals who could be managed solely with lifestyle measures.

“We know how to treat patients at low and high risk for heart disease, but for the estimated 23 million Americans who are at intermediate risk, we still are not certain about the best way to proceed,” said Joseph Yeboah, M.D., assistant professor of cardiology at Wake Forest Baptist and lead author of the study.

The Wake Forest Baptist study, which was funded by the National Heart Lung and Blood Institute (NHLBI) of the National Institutes of Health, evaluated which of the top-tier assessment tools best identified people within the intermediate group who were actually at higher or lower risk.

Determining the relative improvements in prediction afforded by various tests, especially when used in conjunction with the FRS, could help identify intermediate-risk people who may benefit from more aggressive primary prevention interventions, including the use of aspirin and the setting of lower targets for drug treatment of LDL cholesterol and blood pressure, Yeboah said.

Using data from the NHLBI’s Multi-Ethnic Study of Atherosclerosis (MESA) study, the researchers did a head-to-head comparison of six top assessment tests for cardiovascular risk prediction in intermediate-risk people: CAC score, ankle-brachial index, brachial flow mediated dilation, carotid intima-media thickness, high sensitivity C-reactive protein and family history of heart disease.
Of the 6,814 total MESA participants from six communities across the country, 1,330 were considered at intermediate risk and were included in this study. The researchers determined that the CAC score proved the best in predicting which among the intermediate-risk people would go on to have heart disease in the ensuing 7.5 years (average) of follow-up observation.

“If we want to concentrate our attention on the subset of intermediate-risk patients who are at the highest risk for cardiovascular disease, CAC is clearly the best tool we have in our arsenal to identify them. However, we have to look at other factors such as costs and risks associated with radiation exposure from a CT scan before deciding if everyone in the intermediate group should be screened,” Yeboah said.

Additional research is needed to explore the costs, benefits and risks of widespread use of CAC screening in people at risk of heart disease, he said.

The study’s co-authors are: Robyn L. McClelland, Ph.D., University of Washington, Seattle; Tamar S. Polonsky, M.D., University of Chicago; Gregory L. Burke, M.D., Jeffery J. Carr, M.D., and David M. Herrington, M.D., Wake Forest Baptist; Christopher T. Sibley, M.D., National Institutes of Health; Daniel O’Leary, M.D., Tufts Medical Center; David C. Goff Jr., M.D., Ph.D., University of Colorado; and Philip Greenland, M.D., Northwestern University
=============================================================================================================
Read the full article here.

Monday, March 28, 2011

Coronary-Artery Calcium (CAC) imaging

CAC screening improves CAD risk factors without increasing downstream costs: EISNER

March 24, 2011 |                                 Michael O'Riordan
Los Angeles, CA - New data from the Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research (EISNER) study show that noninvasive imaging may actually lead to clinically meaningful improvements in coronary artery disease (CAD) risk factors in healthy individuals. Compared with individuals who did not undergo coronary-artery calcium (CAC) imaging, screening of subclinical atherosclerosis with CAC screening led to an improvement in systolic blood pressure, LDL-cholesterol levels, and a reduction in waist circumference as well as a trend toward greater weight loss among overweight individuals.
The improvements occurred without a significant increase in downstream medical costs, suggesting that CAC screening can play a "gatekeeper" role in determining a need for further noninvasive testing, say investigators.
"We wanted to find out how much impact the scan had on the way that patients take care of themselves, the way they think about changing their lifestyle and doing something about preventing heart disease," senior investigator Dr Daniel Berman (Cedars Sinai Medical Center, Los Angeles, CA) told heartwire. "There have been other studies suggesting an impact on how patients behave after seeing their scan, that as the amount of calcium on the scan went up, patients began to do more about changing their behavior. We noticed the same thing: patients who had a lot of calcium were more likely to do all the things that would prevent heart disease than patients who had less amounts of calcium. Also, the calcium-scoring group did more to change their lifestyle than the patients who did not undergo coronary scanning."
Published online March 23, 2011 in the Journal of the American College of Cardiology with first author Dr Alan Rozanski (St Luke's Roosevelt Hospital, New York), the study included 2137 healthy volunteers randomized to undergo CAC scanning or no coronary-calcium screening. Individuals in the trial were middle-aged and had CAD risk factors but did not have a history of cardiovascular disease.

Change in blood pressure and LDL cholesterol
Of the seven measured risk factors, investigators observed improvements in systolic blood pressure, LDL cholesterol, and a reduction in waist circumference among those who underwent CAC screening.  There was no difference in serum glucose levels, exercise levels, or smoking status between the two treatment arms at four years. CAD risk, as assessed by the Framingham Risk Score (FRS), increased in the no-scan volunteers but remained stable among those who received the CAC scan.
Individuals with higher amounts of calcium were patients who made the larger amount of change.
"Individuals with higher amounts of calcium were patients who made the larger amount of change," said Berman.
The incurred medical costs did not significantly differ between the two treatment arms, with procedure and medication costs totaling $3649 among those who did not undergo CAC screening and $4063 among those who did. The total incurred costs did differ by the amount of coronary calcium observed on the scan, however, with patients having a CAC score >400 significantly more likely to incur more procedural and medication costs than those with less coronary calcium. 
"Overall, in the scanned group vs the no-scan group, the downstream testing costs were similar," Berman told heartwire. "Interestingly, when you look at patients without any coronary calcium, their downstream testing costs were low. Patients who had a lot of calcium, it would be more common for them to go on to additional testing."
Change in clinical risk factors and all incurred medical costs

ParameterNo CAC scan CAC scanp
Systolic blood pressure (mm Hg)
Baseline1301310.03
Change from baseline -5-70.02
LDL cholesterol (mg/dL)
Baseline 1301330.15
Change from baseline-11 -17 0.04
Waist circumference (in)
Baseline 41.041.30.19
Change from baseline100.01
All costs ($)364940630.09

Incurred costs according to CAC score

Medical costs CAC score 0CAC score 1-99CAC score 100-399CAC score >400p (trend)
All costs ($)2623439449009309<0.001

Overall, there was no significant difference in the number of performed procedures among patients who underwent CAC screening. There was a trend toward more lipid-lowering medications being prescribed among those randomized to CAC screening and a significant difference in the number of new blood-pressure-lowering medications prescribed.
In a comparison between volunteers with no observable calcification on the CAC scan with those who did not undergo CAC screening, those with a CAC score of zero were significantly less likely to undergo any stress testing at four years as well as less likely to undergo cardiac catheterization and coronary revascularization. The low-CAC-score patients also incurred significantly less medical costs ($2623 among those with a CAC score of zero vs $3649 for those who did not undergo screening; p<0.001).
The results of the EISNER analysis contrast with the results of a meta-analysis published online March 14, 2011 in the Archives of Internal Medicine. As reported by heartwire, Dr Daniel G Hackam (University of Western Ontario, London) and colleagues assessed seven relevant studies and found no significant changes in the use of drug therapies, exercise, dietary therapy, smoking cessation, or diagnostic coronary catheterization or revascularization based on the results of carotid ultrasound, CAC scans, or other noninvasive imaging techniques.
To heartwire, Berman said that the EISNER data provide support for the recent American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) class IIa recommendation for the use of computed tomography (CT) to measure coronary calcium. According to the ACCF/AHA, the use of CAC "is reasonable for cardiovascular risk assessment in asymptomatic adults at intermediate risk (10% to 20% 10-year risk)."
Berman has research grants from Siemens and GE/Amersham and has both research grants from and is on the speaker's bureau of Astelles and Lantheus.

Sources
  1. Rozanski A, Gransar H, Shaw LJ, et al. Impact of coronary artery calcium scanning on coronary risk factors and downstream testing. J Am Coll Cardiol 2011; DOI:10.1016/j.jacc.2011.01.019. Available at: http://content.onlinejacc.org.
  2. Hackam DG, Shojania KG, Spence JD, et al. Influence of noninvasive cardiovascular imaging in primary prevention: Systematic review and meta-analysis of randomized trials. Arch Intern Med 2011; DOI:10.1001/archinternmed.2011.69. Available at: http://archinte.ama-assn.org.

Monday, February 28, 2011

Coronary Artery Calcium (CAC) Scanning

From: http://www.theheart.org/

Texas Heart Attack Prevention legislation "premature," expert says

February 28, 2011 |                                 Shelley Wood
Dallas, TX - The quiet passage of 2009's Texas Heart Attack Prevention Bill will have ramifications that will "ring loudly" for public health, predicts a Commentary published in the Archives of Internal Medicine this week [1].
As reported in-depth by heartwire, the bill, known as HB 1290, grew out of a bold, unprecedented proposal from the Society for Heart Attack Prevention and Education (SHAPE, a group with no ties to either of the main cardiology professional societies) and mandates insurance coverage at regular intervals for coronary artery calcium (CAC) scanning and carotid ultrasound in the state of Texas. A new bill modeled on the Texas legislation is also poised for consideration in Florida in the coming weeks.
.
.
.
Conspicuously absent, he notes, was any kind of expert testimony from the American Heart Association or American College of Cardiology. As previously reported by heartwire, both societies stayed mum on SHAPE, drawing criticism for their silence, although the ACC told heartwire that their Texas ACC chapter "officially supported this piece of legislation and [was] glad to see that it has passed."
For many prominent cardiologists who were involved in SHAPE—most of whom don't hail from Texas—the bill's passing in some ways validates the work of their organization. Several SHAPE members have told heartwire that they believe their aggressive support for population-based screening fills a void that the professional societies have been too slow to move into.
.
.
.
...that the State of Florida is poised to consider Senate Bill 360, inspired by the Texas bill, which would require insurance reimbursement for up to $200 for CAC and CIMT screening. The bill, sponsored by Florida State Senator Mike Fasano, has been submitted and assigned to committee; the Florida legislature begins its sessions tomorrow.
.
.
.
Asked what he thought about a screening bill now being considered in Florida, Khera said, "In some ways, I can understand why: this is the number-one cause of death, and I certainly appreciate that legislators want to do something, because people are dying from heart disease."
=================================
Read the full article here: